Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs SEC filings (Ticker: RVPHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RVPHW SEC filings page centers on documents that describe the warrant securities associated with Reviva Pharmaceuticals Holdings, Inc. An 8-K filing details a registered public offering in which the company agreed to issue common stock together with Series E and Series F warrants, each exercisable for shares of common stock. These filings are key to understanding the structure and terms of the RVPHW-related warrants.
In the 8-K, Reviva Pharmaceuticals Holdings, Inc. outlines the exercise price, term, and ownership limitations for the warrants. It explains that the warrants are exercisable immediately, may be subject to beneficial ownership caps, and can be exercised on a cashless basis under certain conditions. The filing also describes how the warrants are treated in fundamental transactions, including a right for holders to receive a value based on a Black Scholes formula.
Through Stock Titan, users can access these filings as they appear on the SEC’s EDGAR system, along with AI-powered summaries that help explain the implications of key sections. For RVPHW, this includes the 8-K itself and its exhibits, such as the forms of the Series E and Series F warrants, the securities purchase agreement, and the placement agency agreement. These documents clarify the rights and obligations attached to the warrants and the framework of the related offering.
Investors and researchers can use this page to review how Reviva Pharmaceuticals Holdings, Inc. describes its warrant offerings, the intended use of proceeds for research and development and general corporate purposes, and the contractual terms that govern the RVPHW-linked instruments.
Reviva Pharmaceuticals Holdings, Inc. reports that a Nasdaq Hearings Panel has granted the company an exception to regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing through March 27, 2026. This gives the company more time to bring its share price back above the required level.
The company adds a new risk factor explaining that it may implement a reverse stock split to help meet the bid price rule and that such a split could negatively affect its share price and trading liquidity. Reviva warns that failure to regain or maintain compliance with Nasdaq listing standards could lead to delisting, which could hurt the stock’s liquidity, price, and the company’s ability to raise capital or pursue business opportunities.
Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.
Amendment No. 11 to the Schedule 13D updates beneficial ownership disclosures for Parag Saxena and Vedanta Partners, LLC in Reviva Pharmaceuticals Holdings, Inc. (ticker RVPH). As of the filing date, Vedanta Partners reports beneficial ownership of 5,367,069 shares, representing 5.4% of the 96,337,119 shares outstanding. Mr. Saxena is deemed to beneficially own 6,259,806 shares, or 6.2%, including directly held shares, shares held through related partnerships, vested options and securities underlying warrants and pre-funded warrants. The filing states no transactions occurred in the prior 60 days and explains certain exercise limitations on warrants that prevent ownership above 4.99% for some holders.
Reviva Pharmaceuticals Holdings, Inc. filed a Current Report disclosing that on September 18, 2025 it launched and priced an offering of securities and entered into a Placement Agency Agreement with A.G.P./Alliance Global Partners to market the offering. The company agreed to pay the placement agent a cash fee equal to 7.0% of aggregate gross proceeds (with a 3.5% fee for proceeds from certain investors as mutually agreed) and to reimburse up to $15,000 for non-accountable expenses and up to $75,000 for out-of-pocket accountable legal expenses. The filing references executed forms of Series E and Series F warrants, a securities purchase agreement, the placement agency agreement, legal opinion of Lowenstein Sandler LLP, and press releases announcing the launch and pricing of the offering as exhibits.
The report includes a forward-looking statement caution noting risks to closing the offering and to anticipated proceeds; the filing does not state the final offering size or the exact proceeds expected in this Current Report text.
Reviva Pharmaceuticals Holdings is conducting a primary offering of 27,000,000 shares of common stock, together with Series E warrants for up to 27,000,000 shares and Series F warrants for up to 27,000,000 shares, at a combined public offering price of $0.335 per share and accompanying warrants, for maximum gross proceeds of $9,045,000. After placement fees and expenses, net proceeds are estimated at about $8.1 million, with the company planning to use the cash for research and development of its lead drug brilaroxazine and for working capital.
The offering is a best-efforts, no-minimum deal led by A.G.P., so Reviva may raise substantially less than the maximum and investor funds will not be placed in escrow. Common shares outstanding would be 96,337,119 after the transaction, before any warrant exercises, resulting in dilution for new and existing holders. The Series E warrants are exercisable immediately at $0.335 for five years, while the Series F warrants share the same exercise price with a 12‑month term.
Reviva highlights positive Phase 3 RECOVER-1 data and one‑year open‑label extension results in schizophrenia and plans to seek an FDA meeting in Q4‑2025 to discuss a potential NDA based on existing trials, with a possible NDA filing targeted for Q2‑2026 if the agency response is favorable and additional financing is secured.
Reviva Pharmaceuticals plans a primary offering of common stock, together with Series E and Series F common warrants, and pre-funded warrants sold in lieu of common stock for certain large investors. Each share or pre-funded warrant will be sold with one Series E warrant and one Series F warrant, both exercisable immediately, with the Series E warrant having a five-year term and the Series F warrant a 12‑month term. The transaction is a best‑efforts, no‑minimum offering led by A.G.P./Alliance Global Partners, so proceeds to Reviva will depend on actual investor demand.
Reviva expects to use net proceeds mainly to fund research and development for its lead drug brilaroxazine and for working capital and general corporate purposes. The prospectus highlights positive Phase 3 RECOVER-1 and one‑year open‑label extension results in schizophrenia and outlines a potential path to an NDA submission based on existing Phase 2 and Phase 3 data. The company cautions that investors may face dilution, that the warrants will not be listed, and that limited proceeds could constrain its ability to execute its business plan.